top of page

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...
JMG Logo transparent.png
Executive Spotlights

Beacon Therapeutics Secures $170M in Series B Funding to Accelerate Progress in Ophthalmic Gene Therapy Development

  • Jul 3, 2024
  • 1 min read

London and Cambridge, MA, July 3, 2024 (PRNewswire) -- Beacon Therapeutics has raised $170 million in Series B funding to advance its ophthalmic gene therapy initiatives, supported by Forbion and other investors. The funding will expedite development of AGTC-501 and other pipeline projects, while new appointments strengthen the company's board governance.


Read full article here.

 
 
 

Recent Posts

See All
Novanta to Acquire Riverpoint Medical for $1.2B

Bedford, MA, June 9, 2026 (Novanta) -- Novanta has announced the acquisition of Riverpoint Medical to strengthen its healthcare and surgical solutions portfolio. The transaction expands Novanta’s ca

 
 
 

Comments


Life Science Headlines
bottom of page